

Technology Advisory Committee C Interests Register

Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer

[ID1140]

Publication Date: 25/11/2020

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Prithwiraj Das	TAC C Committee member	Non-financial personal	Dr Das works at Boehringer Ingelheim as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Lytics). He also declared he has not worked on any of the indications under investigation in the last 12 months.	NA	21/11/2019	NA	It was agreed that this declaration would not prevent Dr Das from participating in this discussion